TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04607486

Intervention type: DIAGNOSTIC_TEST
Intervention: 3DfUS and IPSA of leg muscles
Description: 1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait

Intervention type: DIAGNOSTIC_TEST
Intervention: 3DfUS and IPSA of leg muscles
Description: 1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait

Intervention type: DIAGNOSTIC_TEST
Intervention: 3DfUS and IPSA of leg muscles
Description: 1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait
Study: NCT01519323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Cohort 1 (participants \>=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants \<45 kg): starting dose 480 mg
Study: NCT01411826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information + Narratives + Support Group
Description: Information from CDC website Narratives about CRCS written by others Peer social support among study participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Information from CDC website on colon cancer screening.
Study: NCT05378685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
Study: NCT01157702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virus, Vero cell-derived)
Description: One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
Study: NCT04046328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Cholestyramine (ECC) Capsule
Description: Enteric-Coated Delayed Release Cholestyramine Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Cholestyramine (ECC) Capsule
Description: Enteric-Coated Delayed Release Cholestyramine Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Enteric-Coated Delayed Release Placebo Capsules
Study: NCT00301808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium
Description: Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
Study: NCT02544321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01657851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride
Description: Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride
Description: Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
Study: NCT00591682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSX-122
Description: Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~* If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~* If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~* If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort.
Study: NCT01582815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
Study: NCT05450367

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT04441359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemented formula
Description: standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula
Description: standard infant formula not supplemented with prebiotic inulin-type fructans
Study: NCT03290443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 100 mg enasidenib (CC-90007)
Study: NCT03441438

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Serum and urine markers will be obtained after drinking 5 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Serum and urine markers will be obtained after drinking 5 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Serum and urine markers will be obtained after drinking 5 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red wine
Description: Serum and urine markers will be obtained after drinking 5 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red wine
Description: Serum and urine markers will be obtained after drinking 5 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red wine
Description: Serum and urine markers will be obtained after drinking 5 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenolic Compounds
Description: Serum and urine markers will be obtained after consuming 100 mg of provinols powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenolic Compounds
Description: Serum and urine markers will be obtained after consuming 100 mg of provinols powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenolic Compounds
Description: Serum and urine markers will be obtained after consuming 100 mg of provinols powder
Study: NCT04889846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAFE early intervention approach
Description: SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAFE early intervention approach
Description: SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
Study: NCT03149055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
Study: NCT02735239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Anti CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: orally-administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: orally-administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: orally-administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: orally-administered chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV administered Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: IV administered chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: chemo-protective agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV administered chemotherapy
Study: NCT01406886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating rate
Study: NCT00948753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 150 MG
Description: Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
Study: NCT01657851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
Study: NCT00948753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg Phase II
Description: Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
Study: NCT01453049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/glimepiride fix dose combination
Description: oral, once daily, dosage is titrated according to FPG and hypoglycemia events

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: oral, once daily, dosage is titrated according to FPG and hypoglycemia
Study: NCT03327909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAKE vs. HOLD
Description: All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAKE vs. HOLD
Description: All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
Study: NCT00683878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5.0 mg, once daily, up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10.0 mg, once daily, up to 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Dapagliflozin
Description: Tablets, Oral, 0 mg, once daily, up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (Pioglitazone)
Description: Tablets, ≥ 30 mg, Once daily, up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (Pioglitazone)
Description: Tablets, ≥ 30 mg, Once daily, up to 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiazolidinedione (Pioglitazone)
Description: Tablets, ≥ 30 mg, Once daily, up to 48 weeks
Study: NCT02773381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration once-daily.
Study: NCT04355234

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: identify SARS-CoV-2 infection by serology
Description: Blood samples at delivery to identify SARS-CoV-2 infection by serology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collection of biological samples
Description: Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
Study: NCT03481894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kabiven®
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compounded standard parenteral nutrition
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Study: NCT00453154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT03845127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revivent TC Ventricular Enhancement System
Description: Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GDMT
Description: Guideline Directed Medical Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDMT
Description: Guideline Directed Medical Therapy
Study: NCT03392103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: concurrent chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiotherapy
Description: concurrent postoperative radiation therapy
Study: NCT02907034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality experimentation sequency (VR)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality experimentation sequency (VR)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classical narrative approach (CN)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical narrative approach (CN)
Study: NCT02680522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercise training with virtual reality in videogame

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: exercise training with virtual reality in videogame
Study: NCT01693029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 epoetin alfa
Description: Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed epoetin alfa
Description: Solution for subcutaneous injection.
Study: NCT00983307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
Study: NCT04601935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-BCX cells product
Description: In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10\^6 cells/kg, 0.5 × 10\^6 cells/kg, 1.0 × 10\^6 cells/kg, 2.0 × 10\^6 cells/kg, and 4.0 × 10\^6 cells/kg, with 0.25 × 10\^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
Study: NCT04956536

Intervention type: OTHER
Intervention: Demographic data and MRI images were extracted and analyzed
Description: Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
Study: NCT01057953

Intervention type: GENETIC
Group type: NO_INTERVENTION
Intervention: Blood drawn
Description: Blood drawn for patient